Table 1: Characteristics of our patients | ||||||||||||
Patients | Age at onset | Sex | Clinical features | Location | Photosensitivity | Histology | DIF | Serology | Systemic manifetations | Treatment | Follow up | |
1 | 14 years | M | DLE | Face Neck Thorax |
Yes | CLE | ND | N | Absent | Sun protection H-chloroquine |
5 months | |
2 | 15 years | F | DLE | Face Ears |
Yes | CLE | Positive | ANA + | Absent | Sun protection H-chloroquine |
1 month | |
3 | 11 years | F | DLE | Face | Yes | CLE | ND | N | Absent | Sun protection Topical steroids |
2 months | |
4 | 14 years | F | SLE | Face Upper limbs |
Yes | LE | ND | ANA + Antinative DNA + Anti-ENA |
Arthritis | Sun protection H-chloroquine Systemic steroids |
3 months | |
5 | 10 years | M | SLE | Face Lower and upper limbs |
Yes | LE | Positive | ANA + Antinative DNA + Cp |
Lupus nephritis Pericarditis Pleuresy Hemolytic anemia Arterial thrombosis |
Sun protection H-chloroquine Systemic steroids |
8 years | |
6 | 10 years | M | SLE | Face Scalp (alopecia) Thorax Arms |
Yes | LE | Positive | ANA + Cp |
Arthritis | Sun protection H-chloroquine Systemic steroids |
2 months | |
M: male, F: female, DLE: discoid lupus erythematosus, SLE: systemic lupus erythematosus, CLE: chronic lupus erythematosus, ANA: antinuclear antibodies, DIF: direct immunofluorescence, CLE: chronic lupus erythematosus, ND: not done, LE lupus erythematosus, H-chloroquine: hydroxychloroquine. |